论文部分内容阅读
目的探讨重组组织型纤溶酶原激活物静脉溶栓治疗急性脑梗死的临床疗效。方法选取2015年1月—2016年2月巩义市人民医院收治的急性脑梗死患者70例,随机分为对照组与观察组,各35例。对照组患者行阿司匹林抗凝等常规治疗,观察组对照组基础上给予重组组织型纤溶酶原激活剂静脉溶栓治疗,比较两组患者治疗前后美国国立卫生院卒中量表(NIHSS)评分、Barthel指数(BI)评分及不良反应发生情况。结果治疗前两组患者NIHSS评分比较,差异无统计学意义(P>0.05);治疗1、7、14d观察组患者NIHSS评分低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者BI评分比较,差异无统计学意义(P>0.05);治疗后7、14、30d观察组患者BI评分高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组组织型纤溶酶原激活物静脉溶栓治疗急性脑梗死疗效显著,能有效改善患者神经缺损功能及日常生活能力,且不会增加不良反应发生率。
Objective To investigate the clinical efficacy of recombinant tissue plasminogen activator venous thrombolysis in the treatment of acute cerebral infarction. Methods Seventy patients with acute cerebral infarction admitted from Gongyi People’s Hospital from January 2015 to February 2016 were randomly divided into control group and observation group, with 35 cases in each group. Patients in the control group were treated with conventional therapy such as aspirin anticoagulation. The patients in the observation group were given recombinant tissue plasminogen activator intravenous thrombolysis on the basis of the control group. The National Institutes of Health Stroke Scale (NIHSS) score was compared between the two groups before and after treatment. Barthel index (BI) score and adverse reactions. Results There was no significant difference in NIHSS scores between the two groups before treatment (P> 0.05). NIHSS scores in the observation group were lower than those in the control group on the 1st, 14th and 14th days after treatment (P <0.05). There was no significant difference in BI score between the two groups before treatment (P> 0.05). The BI score of observation group was higher than that of control group on the 7th, 14th and 30th day after treatment (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Recombinant tissue plasminogen activator intravenous thrombolytic therapy for acute cerebral infarction significant effect, can effectively improve patients with nerve defect function and daily living ability, and does not increase the incidence of adverse reactions.